Amedisys, Inc. (NASDAQ:AMED) Receives Consensus Rating of “Hold” from Analysts

Amedisys, Inc. (NASDAQ:AMED) has received a consensus recommendation of “Hold” from the five ratings firms that are presently covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $100.75.

A number of research analysts recently weighed in on the company. Wall Street Zen lowered Amedisys from a “strong-buy” rating to a “buy” rating in a report on Saturday. Royal Bank of Canada reissued an “outperform” rating and set a $100.00 price target on shares of Amedisys in a research note on Wednesday, April 16th. Finally, Stephens reissued an “equal weight” rating and issued a $101.00 target price on shares of Amedisys in a report on Tuesday, March 4th.

Institutional Trading of Amedisys

Several hedge funds and other institutional investors have recently bought and sold shares of AMED. Vanguard Group Inc. increased its holdings in Amedisys by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 3,216,120 shares of the health services provider’s stock valued at $291,992,000 after purchasing an additional 10,817 shares in the last quarter. Pentwater Capital Management LP lifted its position in Amedisys by 14.0% during the 1st quarter. Pentwater Capital Management LP now owns 1,345,000 shares of the health services provider’s stock worth $124,587,000 after acquiring an additional 165,000 shares in the last quarter. Alpine Associates Management Inc. raised its stake in shares of Amedisys by 11.7% during the first quarter. Alpine Associates Management Inc. now owns 992,120 shares of the health services provider’s stock valued at $91,900,000 after purchasing an additional 104,000 shares during the period. Norges Bank acquired a new position in shares of Amedisys during the fourth quarter worth $83,061,000. Finally, TIG Advisors LLC increased its stake in Amedisys by 14.5% during the 1st quarter. TIG Advisors LLC now owns 836,417 shares of the health services provider’s stock worth $77,477,000 after buying an additional 106,002 shares during the period. 94.36% of the stock is owned by hedge funds and other institutional investors.

Amedisys Price Performance

Shares of AMED opened at $93.43 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. Amedisys has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The firm has a 50-day simple moving average of $93.36 and a 200-day simple moving average of $91.61. The company has a market capitalization of $3.07 billion, a price-to-earnings ratio of 37.08, a price-to-earnings-growth ratio of 1.78 and a beta of 0.96.

Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.12. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The company had revenue of $594.78 million for the quarter, compared to the consensus estimate of $597.43 million. During the same period last year, the business posted $1.03 EPS. The company’s revenue was up 4.1% on a year-over-year basis. On average, equities research analysts anticipate that Amedisys will post 4.4 earnings per share for the current year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.